Recurrent/Relapsed Rectal Cancer


Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing (January 28, 2016)

The addition of Vectibix® (panitumumab) to best supportive care improves survival over best standard care alone among colorectal cancer patients who have stopped responding to chemotherapy. However, the... Continue Reading

New Treatment Identified for Locally Advanced Rectal Cancer Has Fewer Side Effects Than Current Standard (January 27, 2016)

The results from a comparative phase III clinical study reported by Polish investigators at the 2016 Gastrointestinal Cancers Symposium in San Francisco have identified an additional treatment option for... Continue Reading

Vectibix® Improves Survival in Patients with Wild-Type KRAS Metastatic Colorectal Cancer after Progression on Chemotherapy (August 11, 2015)

Vectibix® (panitumumab) appears to improve overall survival among patients with wild-type KRAS metastatic colorectal cancer that has progressed on or following chemotherapy. A Phase III trial of Vectibix... Continue Reading

XBiotech Launches Website and Call Center to Facilitate Recruitment for U.S. Phase III Study of Xilonix™ in Metastatic Colorectal Cancer (March 17, 2015)

AUSTIN, Texas, March 12, 2015—XBiotech announced today that it has launched a website and call center to help patients with metastatic colorectal cancer learn about its U.S. Pivotal Phase III clinical... Continue Reading

Encouraging Overall Survival and Well-Being for Xilonix™ in Advanced Colorectal Cancer (February 19, 2015)

CancerConnect News: The investigational agent Xilonix™ appears safe and effective for patients with advanced colorectal cancer. These findings were presented at the 2015 Gastrointestinal Cancers Symposium,... Continue Reading

Cyramza Added to FOLFIRI Delays Disease Progression and Extends Survival for Patients With Advanced Colorectal Cancer (January 16, 2015)

The results of an international phase III study evaluating 1,072 patients with advanced colorectal cancer whose disease progressed on or after initial therapy will be presented at the upcoming Gastrointestinal... Continue Reading

Aggressive Chemotherapy Doubles Survival of Patients with Metastatic Colon Cancer (January 15, 2015)

According to the results of a clinical trial presented at the 2015 Gastrointestinal Cancers Symposium in San Francisco, treatment of patients with metastatic colorectal cancer with a four-drug chemotherapy... Continue Reading

Novel Agent Granted Fast Track Designation for Refractory Metastatic Colorectal Cancer (October 23, 2014)

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TAS-102, a novel agent currently under investigation for the treatment of refractory metastatic colorectal cancer. According... Continue Reading

New Online Support Group for People Affected by Gastrointestinal Conditions: IBS, Crohn’s, UC, GERD, Cancer and More (August 14, 2014)

Are you suffering from a gastrointestinal (GI) tract condition? You are not alone! TheGIConnection is now available for patients, caregivers, and health consumers as an up to date online information resource... Continue Reading

Chemotherapy Regimens Paired with Avastin or Erbitux Extended Survival for Patients with Metastatic Colorectal Cancer (June 20, 2014)

In a plenary session of the American Society of Clinical Oncology (ASCO) meeting in Chicago, researchers reported that treatment of metastatic colorectal cancer with Avastin® (bevacizumab) or Erbitux®... Continue Reading

Predicting SIR-Spheres® microspheres Treatment Outcomes for Metastatic Colorectal Cancer (March 5, 2014)

Pre-treatment laboratory tests may play a key role in predicting patient outcomes prior to selective internal radiation therapy for metastatic colorectal cancer, while a new modeling technology for enhancing... Continue Reading

March Is National Colorectal Cancer Awareness Month (March 2, 2014)

Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of colorectal cancer programs for national colorectal cancer awareness month. As the month of March brings colorectal... Continue Reading

Vectibix is Not Inferior to Erbitux in Wild-Type KRAS Metastatic Colorectal Cancer (October 18, 2013)

Vectibix® (panitumumab) was non-inferior to Erbitux® (cetuximab) for overall survival in the treatment of wild-type KRAS metastatic colorectal cancer in patients who have not responded to chemotherapy,... Continue Reading

Erbitux Plus Chemo Boosts Survival in Patients with Colorectal Cancer and Liver Metastases (May 29, 2013)

Adding Erbitux® (cetuximab) to standard chemotherapy might allow some patients with colorectal cancer and inoperable liver metastases to undergo successful surgical resection of the liver metastasis,... Continue Reading

Aspirin May Prolong Life in PIK3CA-Mutated Colorectal Cancers (November 6, 2012)

Daily aspirin use improves survival among patients with mutated-PIK3CA colorectal cancer, according to the results of a study published in the New England Journal of Medicine. Colorectal cancer remains... Continue Reading

Zaltrap Approved for Metastatic Colorectal Cancer (August 15, 2012)

The U.S. Food and Drug Administration (FDA) has approved Zaltrap® (ziv-aflibercept) for use in combination with the FOLFIRI chemotherapy regimen (folinic acid, fluorouracil, and ironotecan) to treat adults... Continue Reading

Regorafenib Shows Promise Against Metastatic Colorectal Cancer (January 19, 2012)

The investigational drug regorafenib improves survival and delays cancer progression among patients with metastatic colorectal cancer that has worsened in spite of other treatments. These results will... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (November 16, 2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS